Endothelin receptor antagonist have been proposed for the treatment of a variety of disorders in which the endothelins may act as pathogenic mediators, such as hypertension,congestive heart failure, and cerebral vasospasm. Bosentan is a nonpeptide competitive|
antagonist, which can be a good tool for studying the endothelin system. It is specific for
the endothelin system and blocks the actions of endothelin at both mammalian receptors
(A and B). Bosentan has recently moved into Phase III clinical trial. This review will attempt to overview the experimental and clinical effects of bosentan.